Immunotherapy with NK cells: recent developments in gene modification open up new avenues

被引：29
作者：
Reindl, Lisa Marie [1 ,2 ]
Albinger, Nawid [1 ,2 ]
Bexte, Tobias [1 ,2 ]
Mueller, Stephan [1 ,2 ]
Hartmann, Jessica [3 ]
Ullrich, Evelyn [1 ,2 ,4 ]
机构：
[1] Goethe Univ Frankfurt, Childrens Hosp, Frankfurt, Germany
[2] Goethe Univ Frankfurt, Expt Immunol, Frankfurt, Germany
[3] Paul Ehrlich Inst, Div Med Biotechnol, Langen, Germany
[4] Goethe Univ, Frankfurt Canc Inst, Frankfurt, Germany
来源：
ONCOIMMUNOLOGY | 2020年 / 9卷 / 01期
关键词：
CAR; NK cells; NK-92; cells; cell therapy; NATURAL-KILLER-CELL; CHIMERIC ANTIGEN RECEPTOR; T-CELLS; MESSENGER-RNA; NK-92; CELLS; HEMATOPOIETIC-CELLS; CORD BLOOD; IN-VITRO; ADOPTIVE TRANSFER; VIVO EXPANSION;
D O I：
10.1080/2162402X.2020.1777651
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Chimeric antigen receptor (CAR)-T cell therapies have achieved remarkable success. However, application-related toxicities, such as cytokine release syndrome or neurotoxicity, moved natural killer (NK) cells into focus as novel players in immunotherapy. CAR-NK cells provide an advantageous dual killing-capacity by CAR-dependent and -independent mechanisms and induce few side effects. While the majority of trials still use CAR-T cells, CAR-NK cell trials are on the rise with 19 ongoing studies worldwide. This review illuminates the current state of research and clinical application of CAR-NK cells, as well as future developmental potential.
引用
收藏
页数：12
相关论文
共 120 条
  • [11] Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens
    Boissel, Laurent
    Betancur, Monica
    Lu, Weiquan
    Wels, Winfried S.
    Marino, Teresa
    Van Etten, Richard A.
    Klingemann, Hans
    [J]. LEUKEMIA & LYMPHOMA, 2012, 53 (05) : 958 - 965
  • [12] Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells
    Boissel, Laurent
    Betancura, Monica
    Wels, Winfried S.
    Tuncer, Hande
    Klingemann, Hans
    [J]. LEUKEMIA RESEARCH, 2009, 33 (09) : 1255 - 1259
  • [13] NK cell education: not an on-off switch but a tunable rheostat
    Brodin, Petter
    Karre, Klas
    Hoglund, Petter
    [J]. TRENDS IN IMMUNOLOGY, 2009, 30 (04) : 143 - 149
  • [14] Tyrosine phosphorylation of a human killer inhibitory receptor recruits protein tyrosine phosphatase 1C
    Campbell, KS
    Dessing, M
    LopezBotet, M
    Cella, M
    Colonna, M
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 184 (01) : 93 - 100
  • [15] Efficient mRNA-Based Genetic Engineering of Human NK Cells with High-Affinity CD16 and CCR7 Augments Rituximab-Induced ADCC against Lymphoma and Targets NK Cell Migration toward the Lymph Node-Associated Chemokine CCL19
    Carlsten, Mattias
    Levy, Emily
    Karambelkar, Amrita
    Li, Linhong
    Reger, Robert
    Berg, Maria
    Peshwa, Madhusudan V.
    Childs, Richard W.
    [J]. FRONTIERS IN IMMUNOLOGY, 2016, 7
  • [16] A Chimeric Receptor with NKG2D Specificity Enhances Natural Killer Cell Activation and Killing of Tumor Cells
    Chang, Yu-Hsiang
    Connolly, John
    Shimasaki, Noriko
    Mimura, Kousaku
    Kono, Koji
    Campana, Dario
    [J]. CANCER RESEARCH, 2013, 73 (06) : 1777 - 1786
  • [17] Natural killer cell lines in tumor immunotherapy
    Min Cheng
    Jian Zhang
    Wen Jiang
    Yongyan Chen
    Zhigang Tian
    [J]. Frontiers of Medicine, 2012, 6 (1) : 56 - 66
  • [18] Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma
    Chmielewski, Markus
    Hombach, Andreas A.
    Abken, Hinrich
    [J]. IMMUNOLOGICAL REVIEWS, 2014, 257 (01) : 83 - 90
  • [19] Targeting CD20+ Aggressive B-cell Non-Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice
    Chu, Yaya
    Hochberg, Jessica
    Yahr, Ashlin
    Ayello, Janet
    van de Ven, Carmella
    Barth, Matthew
    Czuczman, Myron
    Cairo, Mitchell S.
    [J]. CANCER IMMUNOLOGY RESEARCH, 2015, 3 (04) : 333 - 344
  • [20] Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation
    Ciurea, Stefan O.
    Schafer, Jolie R.
    Bassett, Roland
    Denman, Cecele J.
    Cao, Kai
    Willis, Dana
    Rondon, Gabriela
    Chen, Julianne
    Soebbing, Doris
    Kaur, Indreshpal
    Gulbis, Alison
    Ahmed, Sairah
    Rezvani, Katayoun
    Shpall, Elizabeth J.
    Lee, Dean A.
    Champlin, Richard E.
    [J]. BLOOD, 2017, 130 (16) : 1857 - 1868
12345678910